A pan inhibitor of LOX and LOXL1-4 (IC50s = 0.493, 0.159, 0.57, 0.18, and 0.19 µM for fibroblast LOX and recombinant human LOXL1-4, respectively); selective for LOX and LOXL1-4 over DAO, VAP-1, MAO-A, and MAO-B (IC50s = >30 µM for all); reduces bleomycin-induced increases in dermal thickness and the levels of α-smooth muscle actin in a mouse model of systemic sclerosis at 15 mg/kg; reduces collagen crosslinking in KPC CAF 3D organotypic matrices; increases survival to a greater extent than gemcitabine alone when administered in combination with gemcitabine, reduces gemcitabine-induced increases in collagen levels and stiffness, and reduces liver metastatic burden in autochthonous KPC pancreatic ductal adenocarcinoma mouse models at 20 mg/kg